4.7 Review

Rosiglitazone and risk of cancer - A meta-analysis of randomized clinical trials

Related references

Note: Only part of the references are listed.
Article Obstetrics & Gynecology

Polycystic ovary syndrome and endometrial cancer

Rarnesan Navaratnarajah et al.

SEMINARS IN REPRODUCTIVE MEDICINE (2008)

Article Mathematical & Computational Biology

Fixed vs random effects meta-analysis in rare event studies:: The Rosiglitazone link with myocardial infarction and cardiac death

Jonathan J. Shuster et al.

STATISTICS IN MEDICINE (2007)

Article Medicine, General & Internal

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

George A. Diamond et al.

ANNALS OF INTERNAL MEDICINE (2007)

Article Medicine, General & Internal

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes

Steven E. Nissen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Article Oncology

Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes

Rangaswamy Govindarajan et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

Article Medicine, General & Internal

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Steven E. Kahn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Article Medicine, General & Internal

Metformin and reduced risk of cancer in diabetic patients

JMM Evans et al.

BMJ-BRITISH MEDICAL JOURNAL (2005)

Review Medicine, General & Internal

Drug therapy: Thiazolidinediones

H Yki-Jarvinen

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Article Oncology

A phase II trial with rosiglitazone in liposarcoma patients

G Debrock et al.

BRITISH JOURNAL OF CANCER (2003)

Article Multidisciplinary Sciences

Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer

E Mueller et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)